- Gabapentin and pregabalin act on the same calcium channel and share side effects — dizziness, drowsiness, weight gain, edema, and cognitive slowing top the list.
- Pregabalin's effects tend to be more predictable (linear absorption) and it is more often linked to weight gain and fluid retention; gabapentin's side effects can swing more at higher doses.
- Their controlled status differs: pregabalin is a federal Schedule V drug, while gabapentin is NOT federally scheduled but is Schedule V in several states with monitoring in others.
- Both can cause physical dependence; stopping abruptly can trigger withdrawal — and, per updated 2025 FDA labeling, seizures — so any change must be prescriber-supervised.
- Kidney function, age, and other sedating medicines (opioids, alcohol, benzodiazepines) strongly affect side-effect risk.
- This is general drug information, not medical advice, and it contains no dosing or taper schedule to follow on your own — your prescriber decides.
Gabapentinoids are prescribed to tens of millions of Americans every year for neuropathic pain, fibromyalgia, and seizures, and their side effects are often the biggest reason patients stop treatment. The comparison of gabapentin vs pregabalin side effects matters because the drugs work on the same calcium channel but differ in potency, pharmacokinetics, and tolerability. Our medical conditions guide covers nerve pain in more depth. Short answer: pregabalin tends to have more predictable absorption and may cause more weight gain and edema, while gabapentin often causes more dose-related dizziness and sedation at higher doses. Which one is right for you is a decision for your prescriber, not something to self-select.
Quick Comparison Overview
Gabapentin (Neurontin) and pregabalin (Lyrica) both bind to the alpha-2-delta subunit of voltage-gated calcium channels, reducing neurotransmitter release in overactive nerve pathways. Pregabalin is the newer, more potent cousin; milligram for milligram, it produces a stronger effect, which is why its doses are lower. This article focuses specifically on their side effects and tolerability; for a broader head-to-head on uses and effectiveness, see our companion piece on pregabalin vs gabapentin.
According to MedlinePlus, both drugs are FDA-approved for different subsets of neuropathic pain, and both carry recognized (if modest) misuse potential. Their legal status is not identical, though — a point covered in the controlled-substance section below.
Most Common Side Effects
Both drugs share a core set of side effects: dizziness, drowsiness, fatigue, peripheral edema, weight gain, blurred vision, dry mouth, unsteadiness, and difficulty concentrating. These effects are most pronounced in the first 2 to 4 weeks and often fade as the body adapts.
Pregabalin’s side effects tend to appear more predictably because its absorption is linear and dose-proportional. Gabapentin’s absorption saturates at higher doses, meaning patients sometimes experience larger swings in side effects when doses are pushed toward the top of the range. Because responses differ so much between individuals, side effects that are intolerable on one gabapentinoid do not always occur on the other — which is one reason clinicians sometimes switch between them.
Dizziness and Sedation
In clinical trials, dizziness affects roughly 20 to 30% of patients on either drug, and sedation affects 15 to 25%. A Cochrane Review of gabapentin for neuropathic pain found that dizziness was one of the leading reasons for discontinuation. Similar numbers appear in pregabalin trials.
Both drugs amplify the sedating effects of alcohol, opioids, benzodiazepines, and sleep aids. The FDA issued a 2019 safety warning about serious, sometimes life-threatening breathing problems when gabapentinoids are combined with opioids or used in older patients or those with respiratory conditions. This risk is the single most important reason not to combine these drugs with other central-nervous-system depressants without medical guidance.
Weight Gain and Edema
Weight gain is a frequently cited complaint with both drugs, but it appears more prominent with pregabalin in some trials. Gains of 5 to 10 pounds over several months are not unusual, and fluid retention contributes to the total. Pregabalin is more commonly associated with peripheral edema, sometimes enough to prompt a prescriber to reduce the dose or switch drugs.
Gabapentin can also cause weight gain, especially at higher doses, but it is often attributed to increased appetite and reduced activity from sedation rather than direct fluid retention. Anyone with heart failure or kidney disease should have edema evaluated by a clinician rather than assuming it is a benign side effect.
Cognitive and Mood Effects
Both drugs can cause cognitive slowing, word-finding difficulty, and impaired concentration. These effects are usually mild at therapeutic doses but can be significant in older patients or those on higher doses. Pregabalin’s more predictable pharmacokinetics can make cognitive side effects more consistent, while gabapentin’s variable absorption sometimes produces unpredictable “brain fog.”
Mood changes are also reported. Depression, anxiety, and rarely suicidal ideation are listed side effects for both. Updated 2025 FDA labeling emphasizes that suicidal thoughts or behavior have been reported both during treatment and after stopping, so patients and caregivers should watch for new or worsening depression, mood changes, or suicidal thoughts, especially early in treatment or around any dose change, and report them promptly.
Dependence and Withdrawal
Both drugs can cause physical dependence after prolonged use. Abrupt or rapid discontinuation can trigger withdrawal symptoms including insomnia, anxiety, sweating, nausea, pain, and — in some cases — seizures. In 2025 the FDA required updated labeling for gabapentin and pregabalin products describing an increased risk of adverse reactions with abrupt or rapid discontinuation after both short-term and long-term use, reinforcing that these medicines should be tapered gradually under medical supervision rather than stopped suddenly. The safest approach to any change is a prescriber-directed plan; this article does not provide a taper schedule to follow on your own.
Misuse potential exists, particularly in patients with opioid use disorder, where gabapentinoids can enhance opioid effects. That interaction also raises the breathing-problem risk described above.
Emergency callout: Call Poison Control at 1-800-222-1222 for a suspected overdose of either drug. Seek emergency care (call 911) for difficulty breathing, severe drowsiness leading to unresponsiveness, new seizures, or suicidal thoughts. For crisis support, call or text 988; for substance-use help, call SAMHSA’s National Helpline at 1-800-662-4357.
Controlled-Substance Status: An Important Difference
A common misconception is that gabapentin and pregabalin have the same legal status. They do not. Pregabalin is a federally controlled Schedule V substance under the DEA, reflecting a recognized but modest abuse potential. Gabapentin is not federally scheduled, but a number of states have classified it as a Schedule V controlled substance, and additional states require it to be reported to prescription-drug monitoring programs. In practice this means gabapentin prescribing and refills may be handled differently depending on where you live. If you are unsure how your state treats gabapentin, your pharmacist can tell you.
Dosing and Tolerability
Dosing is individualized by the prescriber and is included here only as general background, not as instructions. Gabapentin is commonly started low (often 300 mg at bedtime) and titrated over time, while pregabalin is typically started lower and adjusted more gradually because it is more potent. Slower titration reduces dizziness and sedation meaningfully, which is one reason self-adjusting the dose is discouraged. Do not change your dose, add doses, or stop on your own — ask your prescriber, who will weigh your response, other medicines, and kidney function.
Kidney function matters for both drugs because both are renally cleared. Older patients and those with chronic kidney disease generally require lower doses to avoid excessive side effects, and dosing decisions in these groups belong with a clinician.
Cost and Availability
Generic gabapentin is inexpensive — often under $10 per month with a discount coupon. Generic pregabalin is widely available and has dropped considerably since losing exclusivity, now typically $20 to $40 per month with discount cards, though brand Lyrica is much more expensive. For patients weighing the two on cost grounds alone, gabapentin is usually the cheaper option — but tolerability and your prescriber’s judgment should drive the choice, not price by itself.
Drug Interactions and Warnings
Both drugs interact primarily through additive CNS depression with alcohol, opioids, benzodiazepines, antihistamines, and sleep aids, which can compound sedation and breathing risk. Antacids containing aluminum or magnesium can reduce gabapentin absorption and should generally be spaced by about 2 hours. Always give your prescriber and pharmacist a complete list of your medicines and supplements before starting either drug.
Related reading: see our articles on pregabalin vs gabapentin and Lyrica vs gabapentin for nerve pain.
Frequently Asked Questions
Which drug has fewer side effects overall?
Evidence is mixed, and individual response is the deciding factor. Some patients tolerate gabapentin better; others prefer pregabalin’s more predictable absorption. There is no universally “better tolerated” gabapentinoid — the right choice depends on your body, your other medicines, and your prescriber’s assessment.
Does pregabalin cause more weight gain than gabapentin?
Clinical trials suggest pregabalin has a slightly higher rate of weight gain and edema, though both drugs can contribute. Monitoring weight during the first few months of therapy helps catch significant gains early so your prescriber can respond.
Can I stop these drugs suddenly?
No. Stopping abruptly can cause withdrawal and, in some cases, seizures. Any change should be a gradual, prescriber-supervised taper; chronic users may need a longer, individualized reduction. This article intentionally does not provide a taper schedule.
Are gabapentinoids addictive?
They have lower addiction potential than opioids or benzodiazepines, but physical dependence and misuse do occur, especially in people with other substance use disorders. Pregabalin is a federal Schedule V controlled substance; gabapentin is scheduled only in certain states.
The Bottom Line
Gabapentin and pregabalin share similar side-effect profiles, with dizziness, sedation, weight gain, and edema topping the list. Pregabalin’s effects are more predictable because of linear absorption, and it tends to cause more fluid retention; gabapentin’s side effects can be more variable but the drug is usually cheaper. Their controlled status differs, and both carry updated warnings about withdrawal (including seizures) if stopped abruptly. Tapering slowly under supervision, screening for kidney function, avoiding combinations with opioids or alcohol, and monitoring mood and weight will keep most patients out of trouble. Talk to your prescriber if side effects limit your function — switching between the two drugs sometimes improves tolerability for an individual patient, but that decision is theirs to make with you.
This article is general drug information, not medical advice, and it does not replace your prescriber or pharmacist or contain a dosing or taper schedule to follow on your own. Do not start, stop, switch, or adjust the dose of gabapentin or pregabalin yourself; both can cause dependence, and abrupt discontinuation can cause withdrawal or seizures. Discuss the right medication, dose, and any taper with a qualified clinician. In an emergency call 911; for crisis support call or text 988; for substance-use help call SAMHSA’s National Helpline at 1-800-662-4357.
Sources
- MedlinePlus (NIH/NLM) — gabapentin and pregabalin drug information
- FDA — 2019 Drug Safety Communication on serious breathing problems with gabapentinoids, and 2025 labeling update on abrupt/rapid discontinuation risk and suicidal-behavior monitoring
- DEA / Federal Register — pregabalin Schedule V classification; state-level schedules for gabapentin
- Cochrane Review — gabapentin for chronic neuropathic pain in adults
- Manufacturer prescribing information (Neurontin / Lyrica) and GoodRx — pricing